FI109874B - Päällyste aktiivisen aineen ohjelmoituun vapauttamiseen oraalisesta kiinteästä farmaseuttisesta annostusmuodosta - Google Patents

Päällyste aktiivisen aineen ohjelmoituun vapauttamiseen oraalisesta kiinteästä farmaseuttisesta annostusmuodosta Download PDF

Info

Publication number: FI109874B
Authority: FI; Finland
Prior art keywords: release; coating; coated; dosage form; active ingredient
Prior art date: 1990-07-04

Application number

FI913248A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI913248A0 (fi

FI913248L (fi

Inventor

Franco Pozzi

Pia Furlani

Original Assignee

Zambon Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-04

Filing date

1991-07-04

Publication date

2002-10-31

1990-07-04 Priority claimed from IT02084990A external-priority patent/IT1244867B/it

1990-12-19 Priority claimed from IT02244290A external-priority patent/IT1244037B/it

1991-07-04 Application filed by Zambon Spa filed Critical Zambon Spa

1991-07-04 Publication of FI913248A0 publication Critical patent/FI913248A0/fi

1992-01-05 Publication of FI913248L publication Critical patent/FI913248L/fi

2002-10-31 Application granted granted Critical

2002-10-31 Publication of FI109874B publication Critical patent/FI109874B/fi

Links

239000002552 dosage form Substances 0.000 title claims description 64
239000011248 coating agent Substances 0.000 title claims description 45
238000000576 coating method Methods 0.000 title claims description 45
239000004480 active ingredient Substances 0.000 title claims description 43
239000007787 solid Substances 0.000 title claims description 24
230000002209 hydrophobic effect Effects 0.000 claims description 75
239000010410 layer Substances 0.000 claims description 74
229940079593 drug Drugs 0.000 claims description 45
239000000463 material Substances 0.000 claims description 43
239000004094 surface-active agent Substances 0.000 claims description 42
239000000203 mixture Substances 0.000 claims description 28
239000004203 carnauba wax Substances 0.000 claims description 25
235000013869 carnauba wax Nutrition 0.000 claims description 25
235000013871 bee wax Nutrition 0.000 claims description 22
239000012166 beeswax Substances 0.000 claims description 22
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 19
238000013270 controlled release Methods 0.000 claims description 18
239000002775 capsule Substances 0.000 claims description 17
210000001035 gastrointestinal tract Anatomy 0.000 claims description 11
235000014113 dietary fatty acids Nutrition 0.000 claims description 10
239000000194 fatty acid Substances 0.000 claims description 10
229930195729 fatty acid Natural products 0.000 claims description 10
150000004665 fatty acids Chemical class 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 8
238000002844 melting Methods 0.000 claims description 7
230000008018 melting Effects 0.000 claims description 7
239000004359 castor oil Substances 0.000 claims description 5
235000019438 castor oil Nutrition 0.000 claims description 5
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 5
239000002202 Polyethylene glycol Substances 0.000 claims description 4
150000001298 alcohols Chemical class 0.000 claims description 4
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
235000021355 Stearic acid Nutrition 0.000 claims description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
239000008117 stearic acid Substances 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
229960000541 cetyl alcohol Drugs 0.000 claims description 2
150000002191 fatty alcohols Chemical class 0.000 claims description 2
239000004200 microcrystalline wax Substances 0.000 claims description 2
235000019808 microcrystalline wax Nutrition 0.000 claims description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
239000002736 nonionic surfactant Substances 0.000 claims description 2
239000012188 paraffin wax Substances 0.000 claims description 2
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
239000011247 coating layer Substances 0.000 claims 1
235000011187 glycerol Nutrition 0.000 claims 1
239000012169 petroleum derived wax Substances 0.000 claims 1
235000019381 petroleum wax Nutrition 0.000 claims 1
238000000338 in vitro Methods 0.000 description 65
238000011156 evaluation Methods 0.000 description 49
239000003814 drug Substances 0.000 description 45
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 43
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 43
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 43
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 43
239000003826 tablet Substances 0.000 description 43
238000002360 preparation method Methods 0.000 description 31
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
238000012360 testing method Methods 0.000 description 26
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
238000000034 method Methods 0.000 description 19
238000001727 in vivo Methods 0.000 description 18
238000011978 dissolution method Methods 0.000 description 17
210000001072 colon Anatomy 0.000 description 15
239000008118 PEG 6000 Substances 0.000 description 14
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 14
238000007906 compression Methods 0.000 description 13
230000006835 compression Effects 0.000 description 12
238000009505 enteric coating Methods 0.000 description 11
239000002702 enteric coating Substances 0.000 description 11
229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
239000001267 polyvinylpyrrolidone Substances 0.000 description 11
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
230000001681 protective effect Effects 0.000 description 11
235000019359 magnesium stearate Nutrition 0.000 description 10
229920000642 polymer Polymers 0.000 description 10
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 10
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
239000008101 lactose Substances 0.000 description 9
238000011282 treatment Methods 0.000 description 9
230000001419 dependent effect Effects 0.000 description 8
-1 encephalins Chemical compound 0.000 description 8
JILLNVBIEKMQLV-UHFFFAOYSA-N 1-(3-bromo-1,2-oxazol-5-yl)-2-(tert-butylamino)ethanol;hydron;chloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Br)=NO1 JILLNVBIEKMQLV-UHFFFAOYSA-N 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
239000012528 membrane Substances 0.000 description 7
239000008363 phosphate buffer Substances 0.000 description 7
238000004007 reversed phase HPLC Methods 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
239000003480 eluent Substances 0.000 description 6
235000012054 meals Nutrition 0.000 description 6
210000002784 stomach Anatomy 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
229920002261 Corn starch Polymers 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
239000013543 active substance Substances 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
238000007922 dissolution test Methods 0.000 description 5
239000001087 glyceryl triacetate Substances 0.000 description 5
235000013773 glyceryl triacetate Nutrition 0.000 description 5
239000000454 talc Substances 0.000 description 5
229910052623 talc Inorganic materials 0.000 description 5
229960002622 triacetin Drugs 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
239000005662 Paraffin oil Substances 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000008119 colloidal silica Substances 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
239000007884 disintegrant Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000007888 film coating Substances 0.000 description 4
238000009501 film coating Methods 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
ALIXRWKJZYLBJI-UHFFFAOYSA-N [4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate;hydrochloride Chemical compound Cl.CNCCC1=CC=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=C1 ALIXRWKJZYLBJI-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
229920006318 anionic polymer Polymers 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229960001216 ibopamine hydrochloride Drugs 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000002195 soluble material Substances 0.000 description 3
238000002798 spectrophotometry method Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
102400000739 Corticotropin Human genes 0.000 description 2
101800000414 Corticotropin Proteins 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
102400000921 Gastrin Human genes 0.000 description 2
108010052343 Gastrins Proteins 0.000 description 2
102400000321 Glucagon Human genes 0.000 description 2
108060003199 Glucagon Proteins 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
102000018997 Growth Hormone Human genes 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
108010079943 Pentagastrin Proteins 0.000 description 2
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
238000003556 assay Methods 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
238000009835 boiling Methods 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
102000038379 digestive enzymes Human genes 0.000 description 2
108091007734 digestive enzymes Proteins 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
229960004666 glucagon Drugs 0.000 description 2
WDKXLLJDNUBYCY-UHFFFAOYSA-N ibopamine Chemical compound CNCCC1=CC=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=C1 WDKXLLJDNUBYCY-UHFFFAOYSA-N 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
229960004963 mesalazine Drugs 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229960002009 naproxen Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229960000444 pentagastrin Drugs 0.000 description 2
ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229940075630 samarium oxide Drugs 0.000 description 2
229910001954 samarium oxide Inorganic materials 0.000 description 2
FKTOIHSPIPYAPE-UHFFFAOYSA-N samarium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Sm+3].[Sm+3] FKTOIHSPIPYAPE-UHFFFAOYSA-N 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
238000003756 stirring Methods 0.000 description 2
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 2
229960003386 triazolam Drugs 0.000 description 2
239000001993 wax Substances 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
DTBDAFLSBDGPEA-UHFFFAOYSA-N 3-Methylquinoline Natural products C1=CC=CC2=CC(C)=CN=C21 DTBDAFLSBDGPEA-UHFFFAOYSA-N 0.000 description 1
CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
241000819038 Chichester Species 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000019399 Colonic disease Diseases 0.000 description 1
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
102000009025 Endorphins Human genes 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
229920003085 Kollidon® CL Polymers 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229960004538 alprazolam Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
229940124350 antibacterial drug Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229940127225 asthma medication Drugs 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
235000015895 biscuits Nutrition 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
229950008847 broxaterol Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000306 component Substances 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
239000008358 core component Substances 0.000 description 1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
229960001193 diclofenac sodium Drugs 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical class CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
239000007919 dispersible tablet Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000004880 explosion Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
229960004370 ibopamine Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000011229 interlayer Substances 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
238000002386 leaching Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229940079480 naproxen 250 mg Drugs 0.000 description 1
239000008184 oral solid dosage form Substances 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000008019 pharmaceutical lubricant Substances 0.000 description 1
230000010399 physical interaction Effects 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229940057847 polyethylene glycol 600 Drugs 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
239000007944 soluble tablet Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
239000004173 sunset yellow FCF Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003760 tallow Substances 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
229940102089 triazolam 0.125 mg Drugs 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FI913248A 1990-07-04 1991-07-04 Päällyste aktiivisen aineen ohjelmoituun vapauttamiseen oraalisesta kiinteästä farmaseuttisesta annostusmuodosta FI109874B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
IT2084990		1990-07-04
IT02084990A IT1244867B (it)	1990-07-04	1990-07-04	Forma farmaceutica a rilascio rapido ritardato
IT2244290		1990-12-19
IT02244290A IT1244037B (it)	1990-12-19	1990-12-19	Forma farmaceutica a rilascio selettivo nel colon

Publications (3)

Publication Number	Publication Date
FI913248A0 FI913248A0 (fi)	1991-07-04
FI913248L FI913248L (fi)	1992-01-05
FI109874B true FI109874B (fi)	2002-10-31

Family

ID=26327684

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI913248A FI109874B (fi)	1990-07-04	1991-07-04	Päällyste aktiivisen aineen ohjelmoituun vapauttamiseen oraalisesta kiinteästä farmaseuttisesta annostusmuodosta

Country Status (23)

Country	Link
US (3)	US5310558A (hu)
JP (1)	JPH0624961A (hu)
AT (1)	AT400295B (hu)
AU (1)	AU638583B2 (hu)
BE (1)	BE1004882A3 (hu)
CA (1)	CA2044398C (hu)
CH (1)	CH683498A5 (hu)
DE (1)	DE4122039A1 (hu)
DK (1)	DK129591A (hu)
ES (1)	ES2036457B1 (hu)
FI (1)	FI109874B (hu)
FR (1)	FR2664163B1 (hu)
GB (1)	GB2245492B (hu)
GR (1)	GR1002564B (hu)
HU (2)	HUT59591A (hu)
IE (1)	IE61651B1 (hu)
IL (1)	IL98525A (hu)
LU (1)	LU87964A1 (hu)
NL (1)	NL9101161A (hu)
NO (1)	NO304579B1 (hu)
PT (1)	PT98188B (hu)
RU (1)	RU2012330C1 (hu)
SE (1)	SE512373C2 (hu)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5372823A (en) *	1989-03-16	1994-12-13	Bristol-Myers Squibb Company	Direct compression cholestyramine tablet and solvent-free coating thereof
US6482516B1 (en) *	1993-07-20	2002-11-19	Banner Pharmacaps, Inc.	Enrobed tablet
IE61651B1 (en) *	1990-07-04	1994-11-16	Zambon Spa	Programmed release oral solid pharmaceutical dosage form
US5571533A (en) *	1992-02-07	1996-11-05	Recordati, S.A., Chemical And Pharmaceutical Company	Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
AU3949093A (en) *	1992-03-31	1993-11-08	Benzon Pharma A/S	A pharmaceutical formulation
GB2267219B (en) *	1992-05-28	1996-04-03	Elan Corp Plc	Differential release tablet with multiple active agents
US5500227A (en) *	1993-11-23	1996-03-19	Euro-Celtique, S.A.	Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en)	1993-11-23	2001-04-03	Euro-Celtique S.A.	Immediate release tablet cores of acetaminophen having sustained-release coating
GB9325445D0 (en)	1993-12-13	1994-02-16	Cortecs Ltd	Pharmaceutical formulations
FR2717388B1 (fr) *	1994-03-21	1996-11-22	Synthelabo	Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.
FR2723536A1 (fr) *	1994-08-11	1996-02-16	Seth Pawan	Composition permettant une liberation selective d'un principe actif
EP0742008A1 (en) *	1995-05-11	1996-11-13	Euro-Celtique S.A.	Controlled release pharmaceutical formulations
US5773031A (en) *	1996-02-27	1998-06-30	L. Perrigo Company	Acetaminophen sustained-release formulation
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
ATE380235T1 (de) *	1996-12-06	2007-12-15	Procter & Gamble	Beschichtetes reinigungsmittel in tablettenform
AU5775398A (en) *	1996-12-17	1998-07-15	Poli Industria Chimica S.P.A.	Site-specific controlled release dosage formulation for mesalamine
US5914134A (en) *	1997-01-27	1999-06-22	Wockhardt Europe Limited	Process for the pulsatile delivery of diltiazem HCL and product produced thereby
NL1005948C2 (nl) *	1997-05-01	1998-11-09	Inst Voor Agrotech Onderzoek	Omhulde stof met gecontroleerde afgifte.
NL1007696C1 (nl) *	1997-05-01	1998-11-03	Inst Voor Agrotech Onderzoek	Omhulde stof met gecontroleerde afgifte.
ZA984591B (en) *	1997-06-09	1998-12-08	Ambi Inc	A method for the treatment of diarrheal disease and for elmininating particular bacterial populations from the colon
US20060116330A1 (en) *	1997-07-08	2006-06-01	The Iams Company	Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en)	1997-07-08	2013-10-22	The Iams Company	Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) *	1997-07-08	2002-03-21	Josef Pitha	Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
NZ503086A (en)	1997-08-29	2002-03-01	Upjohn Co	An orally administrable pharmaceutical composition comprising an inner core and two outer layers, which render it substantially free of unpleasant tastes
ES2157731B1 (es) *	1998-07-21	2002-05-01	Liconsa Liberacion Controlada	Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
US6638534B1 (en) *	1998-07-28	2003-10-28	Tanabe Seiyaku Co., Ltd.	Preparation capable of releasing drug at target site in intestine
US20070122481A1 (en) *	1998-11-02	2007-05-31	Elan Corporation Plc	Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20090149479A1 (en) *	1998-11-02	2009-06-11	Elan Pharma International Limited	Dosing regimen
US20060240105A1 (en) *	1998-11-02	2006-10-26	Elan Corporation, Plc	Multiparticulate modified release composition
US20090297597A1 (en) *	1998-11-02	2009-12-03	Gary Liversidge	Modified Release Ticlopidine Compositions
CN100444830C (zh)	1998-11-02	2008-12-24	伊兰公司，Plc	多颗粒改进释放组合物
EP1005863A1 (en)	1998-12-04	2000-06-07	Synthelabo	Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6419960B1 (en)	1998-12-17	2002-07-16	Euro-Celtique S.A.	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US20030170181A1 (en) *	1999-04-06	2003-09-11	Midha Kamal K.	Method for preventing abuse of methylphenidate
EP1191924A4 (en)	1999-04-06	2005-02-09	Pharmaquest Ltd	PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT ADMINISTRATION OF (D-THREO) -METHYLPHENIDATE AND A SECOND STIMULANT OF THE CENTRAL NERVOUS SYSTEM
CN1365275A (zh) *	1999-06-07	2002-08-21	南诺斯菲尔股份有限公司	包被颗粒的方法以及所得颗粒
ITMI991316A1 (it) *	1999-06-14	2000-12-14	Cip Ninety Two 92 S A	Composizioni farmaceutiche orali a rilascio modificato di mesalazina
EP1064937A1 (en) *	1999-06-28	2001-01-03	Sanofi-Synthelabo	Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
RU2230556C2 (ru)	1999-10-29	2004-06-20	Эро-Селтик, С.А.	Препаративные формы гидрокодона с контролируемым высвобождением
WO2001054671A1 (fr) *	2000-01-27	2001-08-02	Tanabe Seiyaku Co., Ltd.	Preparation a liberation prolongee et son procede de fabrication
HUP0300491A2 (en) *	2000-02-28	2003-07-28	Vectura Ltd	Improvements in or relating to the delivery of oral drugs
WO2001064191A1 (de) *	2000-02-28	2001-09-07	Akzo Nobel N.V.	Körper für die kontrollierte abgabe von wirkstoffen
DE10012199A1 (de) *	2000-03-13	2001-09-20	Haarmann & Reimer Gmbh	Eingekapselte Substanzen mit kontrollierter Freisetzung
US6635277B2 (en)	2000-04-12	2003-10-21	Wockhardt Limited	Composition for pulsatile delivery of diltiazem and process of manufacture
ATE401095T1 (de) *	2000-05-26	2008-08-15	Frohwitter Bernhard	Mittel zum erhalten und/oder korrigieren der blutglukosekonzentration
ES2185452B2 (es) *	2000-08-01	2004-03-16	Cinfa S A Lab	Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
HU230875B1 (hu)	2000-10-30	2018-11-29	Euro-Celtique S.A.	Szabályozott hatóanyag-leadású hidrokodon készítmények
IL157634A0 (en) *	2001-03-13	2004-03-28	Penwest Pharmaceuticals Co	Chronotherapeutic dosage forms containing glucocorticosteroid
US8218183B2 (en) *	2001-07-31	2012-07-10	Transpacific Systems, Llc	Scanning speed control device and method
US7248387B2 (en)	2001-07-31	2007-07-24	Umax Data Systems, Inc.	Scanning speed control device and method
US6500454B1 (en)	2001-10-04	2002-12-31	Eurand Pharmaceuticals Ltd.	Timed, sustained release systems for propranolol
US9358214B2 (en)	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
JP4031232B2 (ja) *	2001-11-09	2008-01-09	カプスゲル・ジャパン株式会社	新規カプセル
US9308220B2 (en)	2001-12-11	2016-04-12	Cosmo Technologies Limited	Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
ITMI20012599A1 (it) *	2001-12-11	2003-06-11	Cosmo Spa	Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US20050025824A1 (en) *	2001-12-14	2005-02-03	Eurand Pharmaceuticals Ltd.	Pulsatile release histamine H2 antagonist dosage form
US6663888B2 (en) *	2001-12-14	2003-12-16	Eurand Pharmaceuticals Ltd.	Pulsatile release histamine H2 antagonist dosage form
DE60222803T2 (de) *	2001-12-21	2008-07-17	Supernus Pharmaceuticals, Inc.	Orale kapselformulierung mit verbesserter physikalischer stabilität
US7125563B2 (en) *	2002-04-12	2006-10-24	Dava Pharmaceuticals, Inc.	Sustained release pharmaceutical preparations and methods for producing the same
US8168170B2 (en) *	2002-10-03	2012-05-01	The Procter And Gamble Company	Compositions having an inner core and at least three surrounding layers
US20080220074A1 (en) *	2002-10-04	2008-09-11	Elan Corporation Plc	Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
RU2221559C1 (ru) *	2002-11-15	2004-01-20	Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин"	Препарат диклофенак натрия длительного действия
US8367111B2 (en)	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
JP4790597B2 (ja)	2003-04-24	2011-10-12	ヤゴテックアーゲー	規定されたコア幾何学的配置を有する遅延放出錠
WO2005027878A1 (en) *	2003-09-19	2005-03-31	Penwest Pharmaceuticals Co.	Delayed released dosage forms
AU2004273958A1 (en) *	2003-09-19	2005-03-31	Penwest Pharmaceuticals Co.	Chronotherapeutic dosage forms
US20050152884A1 (en)	2003-12-19	2005-07-14	The Procter & Gamble Company	Canine probiotic Bifidobacteria globosum
US8877178B2 (en)	2003-12-19	2014-11-04	The Iams Company	Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en)	2003-12-19	2010-08-31	The Procter & Gamble Company	Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en)	2003-12-19	2014-11-25	The Iams Company	Canine probiotic Lactobacilli
US20050158294A1 (en)	2003-12-19	2005-07-21	The Procter & Gamble Company	Canine probiotic Bifidobacteria pseudolongum
RU2267318C1 (ru) *	2004-05-25	2006-01-10	Закрытое акционерное общество "ФАРМАПЭК"	Пролонгированный антиангинальный препарат изосорбида динитрата и способ его получения
ITMI20041295A1 (it)	2004-06-25	2004-09-25	Cosmo Spa	Composizioni farmaceutiche antimicrobiche orali
US8747895B2 (en) *	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
ES2409347T3 (es)	2004-10-21	2013-06-26	Aptalis Pharmatech, Inc.	Composiciones farmacéuticas de sabor enmascarado con agentes porogénicos gastrosolubles
US20060105038A1 (en) *	2004-11-12	2006-05-18	Eurand Pharmaceuticals Limited	Taste-masked pharmaceutical compositions prepared by coacervation
JP4916163B2 (ja) *	2004-12-01	2012-04-11	エーザイ・アール・アンド・ディー・マネジメント株式会社	カプセル用コーティング剤
WO2006063078A2 (en) *	2004-12-08	2006-06-15	Elan Corporation, Plc	Topiramate pharmaceuticals composition
US20070298098A1 (en) *	2005-02-16	2007-12-27	Elan Pharma International Limited	Controlled Release Compositions Comprising Levetiracetam
KR20080007586A (ko) *	2005-04-12	2008-01-22	엘란 파마 인터내셔널 리미티드	세균감염증의 치료를 위한 세팔로스포린 함유 조절 방출조성물
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
US20060280788A1 (en) *	2005-05-09	2006-12-14	Casey Stephen M	Delivery and formulations of mast cell stabilizers
AU2006253007B2 (en)	2005-05-31	2012-12-20	Alimentary Health Ltd	Feline probiotic Bifidobacteria
CA2609617C (en)	2005-05-31	2014-07-08	The Iams Company	Feline probiotic lactobacilli
WO2007037790A2 (en) *	2005-06-08	2007-04-05	Elan Corporation, Plc	Modified release famciclovir compositions
US20070020333A1 (en) *	2005-07-20	2007-01-25	Chin-Chih Chiang	Controlled release of hypnotic agents
EP1909769A2 (en) *	2005-08-01	2008-04-16	Alpharma, Inc.	Alcohol resistant pharmaceutical formulations
US20070036859A1 (en) *	2005-08-11	2007-02-15	Perry Ronald L	Sustained release antihistamine and decongestant composition
WO2007065559A1 (en)	2005-11-18	2007-06-14	Synthon B.V.	Zolpidem tablets
EP2049123B2 (en)	2006-08-03	2016-08-24	Horizon Pharma AG	Delayed-release glucocorticoid treatment of rheumatoid disease
RU2436581C2 (ru)	2007-02-01	2011-12-20	Дзе Иамс Компани	Способ уменьшения воспаления и снижения стресса у млекопитающего
US8486452B2 (en) *	2007-07-20	2013-07-16	Mylan Pharmaceuticals Inc.	Stabilized tolterodine tartrate formulations
US8110226B2 (en) *	2007-07-20	2012-02-07	Mylan Pharmaceuticals Inc.	Drug formulations having inert sealed cores
US20090036414A1 (en) *	2007-08-02	2009-02-05	Mutual Pharmaceutical Company, Inc.	Mesalamine Formulations
FR2920431B1 (fr)	2007-08-29	2010-03-12	Essilor Int	Procede de preparation d'un materiau transparent de type alliage de polymere thermodurcissable/polymere thermoplastique et son application dans l'optique pour la fabrication de verres organiques.
FR2920337B1 (fr)	2007-08-29	2010-03-12	Essilor Int	Procede de preparation d'un article moule transparent a base d'un alliage de polymere thermoplastique et de polymere thermodurcissable
US9771199B2 (en)	2008-07-07	2017-09-26	Mars, Incorporated	Probiotic supplement, process for making, and packaging
US10104903B2 (en)	2009-07-31	2018-10-23	Mars, Incorporated	Animal food and its appearance
CN102958515A (zh)	2009-12-02	2013-03-06	阿普塔利斯制药有限公司	非索非那定微胶囊及含有非索非那定微胶囊的组合物
US20150164920A1 (en)	2012-03-30	2015-06-18	Laboratorios Del Dr. Esteve S.A.	Controlled release formulation comprising mesalamine
CA2936740C (en)	2014-10-31	2017-10-10	Purdue Pharma	Methods and compositions particularly for treatment of attention deficit disorder
GB201420306D0 (en)	2014-11-14	2014-12-31	Bio Images Drug Delivery Ltd	Compositions
GB201420300D0 (en)	2014-11-14	2014-12-31	Bio Images Drug Delivery Ltd	Tablet
GB201420311D0 (en) *	2014-11-14	2014-12-31	Bio Images Drug Delivery Ltd	Pharmaceutical processing
WO2016174664A1 (en)	2015-04-29	2016-11-03	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
US10722473B2 (en)	2018-11-19	2020-07-28	Purdue Pharma L.P.	Methods and compositions particularly for treatment of attention deficit disorder
US11504327B1 (en)	2019-01-21	2022-11-22	Eric Morrison	Method of preparing nanoparticles by hot-melt extrusion
EP4622671A1 (en) *	2022-11-21	2025-10-01	Eric Morrison	Nanoparticle dispersions comprising therapeutic agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2373763A (en) *	1941-11-24	1945-04-17	State Of Iowa	Enteric coating
DE1482489A1 (de) *	1965-01-13	1970-03-12	Boehringer Mannheim Gmbh	Vollautomatisches Dragierverfahren
US3438797A (en) *	1965-10-21	1969-04-15	Jerry Allen Biddle Sr	Method of preparing pharmaceutical tablets
FR2284318A1 (fr) *	1974-09-13	1976-04-09	Rech Ind Therapeutiqu	Compositions d'antibiotiques du type virginiamycine pour administration orale
GB1594102A (en) *	1977-09-26	1981-07-30	Sankyo Co	Ingestible coating compositions
JPS54143518A (en) *	1978-04-26	1979-11-08	Shin Etsu Chem Co Ltd	Method for producing coating composition for solid preparation
US4341563A (en) *	1978-11-17	1982-07-27	Sankyo Company Limited	Protective coating compositions
FR2471186A1 (fr) *	1979-12-10	1981-06-19	Roussel Uclaf	Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
JPS56140915A (en) *	1980-04-07	1981-11-04	Yamanouchi Pharmaceut Co Ltd	Pharmaceutical preparation for solid drug
DE3024416C2 (de) *	1980-06-28	1982-04-15	Gödecke AG, 1000 Berlin	Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4347237A (en) *	1981-03-02	1982-08-31	Evenstad Kenneth L	Lower fatty acid glyceride high-HLB lubricating suppository and method for making and using the same
US4609543A (en) *	1983-11-14	1986-09-02	Nabisco Brands, Inc.	Soft homogeneous antacid tablet
JPS60169416A (ja) *	1984-02-14	1985-09-02	Taisho Pharmaceut Co Ltd	素錠の表面処理方法
US4755387A (en) *	1985-03-21	1988-07-05	The Procter & Gamble Company	Therapeutic particles
US5023108A (en) *	1986-01-13	1991-06-11	Research Corporation	Aqueous dispersions of waxes and lipids for pharmaceutical coating
DE3838094A1 (de) *	1988-11-10	1990-05-17	Nordmark Arzneimittel Gmbh	Feste pharmazeutische retardform
IE61651B1 (en) *	1990-07-04	1994-11-16	Zambon Spa	Programmed release oral solid pharmaceutical dosage form

1991
- 1991-06-11 IE IE197891A patent/IE61651B1/en not_active IP Right Cessation
- 1991-06-12 CA CA002044398A patent/CA2044398C/en not_active Expired - Fee Related
- 1991-06-17 IL IL9852591A patent/IL98525A/en not_active IP Right Cessation
- 1991-06-25 CH CH1890/91A patent/CH683498A5/fr not_active IP Right Cessation
- 1991-06-26 LU LU87964A patent/LU87964A1/fr unknown
- 1991-06-26 FR FR9107861A patent/FR2664163B1/fr not_active Expired - Fee Related
- 1991-06-27 GR GR910100283A patent/GR1002564B/el not_active IP Right Cessation
- 1991-07-01 AT AT0131091A patent/AT400295B/de not_active IP Right Cessation
- 1991-07-02 PT PT98188A patent/PT98188B/pt not_active IP Right Cessation
- 1991-07-03 RU SU915001025A patent/RU2012330C1/ru active
- 1991-07-03 ES ES9101560A patent/ES2036457B1/es not_active Expired - Fee Related
- 1991-07-03 DK DK129591A patent/DK129591A/da not_active Application Discontinuation
- 1991-07-03 SE SE9102072A patent/SE512373C2/sv not_active IP Right Cessation
- 1991-07-03 BE BE9100633A patent/BE1004882A3/fr not_active IP Right Cessation
- 1991-07-03 GB GB9114363A patent/GB2245492B/en not_active Expired - Fee Related
- 1991-07-03 DE DE4122039A patent/DE4122039A1/de not_active Withdrawn
- 1991-07-03 NL NL9101161A patent/NL9101161A/nl active Search and Examination
- 1991-07-03 NO NO912607A patent/NO304579B1/no not_active IP Right Cessation
- 1991-07-04 JP JP3261480A patent/JPH0624961A/ja active Pending
- 1991-07-04 FI FI913248A patent/FI109874B/fi active
- 1991-07-04 HU HU912266A patent/HUT59591A/hu unknown
- 1991-07-04 AU AU80199/91A patent/AU638583B2/en not_active Ceased
1993
- 1993-02-09 US US08/015,669 patent/US5310558A/en not_active Expired - Lifetime
1994
- 1994-01-10 US US08/179,227 patent/US5445828A/en not_active Expired - Lifetime
1995
- 1995-04-17 US US08/422,945 patent/US5629017A/en not_active Expired - Lifetime
- 1995-06-26 HU HU95P/P00435P patent/HU211936A9/hu unknown

Also Published As

Publication number	Publication date
DE4122039A1 (de)	1992-01-09
DK129591D0 (da)	1991-07-03
AT400295B (de)	1995-11-27
PT98188B (pt)	1998-12-31
US5445828A (en)	1995-08-29
JPH0624961A (ja)	1994-02-01
CA2044398C (en)	2000-07-18
GR910100283A (el)	1992-08-26
GB2245492A (en)	1992-01-08
PT98188A (pt)	1992-05-29
IE911978A1 (en)	1992-01-15
NO304579B1 (no)	1999-01-18
ES2036457B1 (es)	1994-03-01
SE512373C2 (sv)	2000-03-06
GB2245492B (en)	1994-03-02
HUT59591A (en)	1992-06-29
CA2044398A1 (en)	1992-01-05
US5629017A (en)	1997-05-13
FR2664163A1 (fr)	1992-01-10
HU912266D0 (en)	1991-12-30
GR1002564B (el)	1997-02-03
IE61651B1 (en)	1994-11-16
NL9101161A (nl)	1992-02-03
RU2012330C1 (ru)	1994-05-15
IL98525A0 (en)	1992-07-15
AU638583B2 (en)	1993-07-01
ES2036457A1 (es)	1993-05-16
SE9102072D0 (sv)	1991-07-03
BE1004882A3 (fr)	1993-02-16
DK129591A (da)	1992-01-05
FR2664163B1 (fr)	1995-06-09
IL98525A (en)	1996-07-23
SE9102072L (sv)	1992-01-05
FI913248A0 (fi)	1991-07-04
AU8019991A (en)	1992-01-09
LU87964A1 (fr)	1992-03-03
NO912607L (no)	1992-01-06
GB9114363D0 (en)	1991-08-21
NO912607D0 (no)	1991-07-03
US5310558A (en)	1994-05-10
ATA131091A (de)	1995-04-15
CH683498A5 (fr)	1994-03-31
HU211936A9 (en)	1996-01-29
FI913248L (fi)	1992-01-05

Publication	Publication Date	Title
FI109874B (fi)	2002-10-31	Päällyste aktiivisen aineen ohjelmoituun vapauttamiseen oraalisesta kiinteästä farmaseuttisesta annostusmuodosta
CA1264293A (en)	1990-01-09	Process for producing controlled-release multiple units pharmaceutical formulation
KR100280099B1 (ko)	2001-02-01	방출 개시 제어 및 방출 속도 제어형 제제
Gazzaniga et al.	2006	Time-controlled oral delivery systems for colon targeting
EP2074992B1 (en)	2015-05-20	Oral pharmaceutical formulations comprising salts of fenofibric acid
US5830503A (en)	1998-11-03	Enteric coated diltiazem once-a-day formulation
KR20050084589A (ko)	2005-08-26	암페타민 염을 함유한 서방출성 제제
US20090017110A1 (en)	2009-01-15	Modified release formulations of anti-irritability drugs
WO2010075080A1 (en)	2010-07-01	A method of treating insomnia
EP1916995B1 (en)	2015-10-28	Ph-controlled pulsatile delivery system, methods for preparation and use thereof
MX2008014455A (es)	2008-11-27	Sistema de suministro de farmaco de dosis controlada.
KR100369698B1 (ko)	2003-01-30	서트랄린의 지연-방출성 투여 형태
AU684786B2 (en)	1998-01-08	A drug delivery composition for alpha-adreno receptor blocking agents
EP2298290A1 (en)	2011-03-23	Controlled release composition comprising levetiracetam
US20070185199A1 (en)	2007-08-09	Pharmaceutical formulations
US20070148234A1 (en)	2007-06-28	Pharmaceutical formulations
HK1210042B (en)	2018-06-08	Pharmaceutical compositions comprising hydromorphone and naloxone